- Home
- PRFX vs GRI Comparison
PRFX vs GRI Comparison
Compare PRFX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- GRI
- Stock Information
- Founded
- PRFX 2007
- GRI 2018
- Country
- PRFX Israel
- GRI United States
- Employees
- PRFX N/A
- GRI N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- GRI Health Care
- Exchange
- PRFX Nasdaq
- GRI Nasdaq
- Market Cap
- PRFX 1.6M
- GRI 1.5M
- IPO Year
- PRFX 2020
- GRI N/A
- Fundamental
- Price
- PRFX $0.62
- GRI $0.47
- Analyst Decision
- PRFX Strong Buy
- GRI Strong Buy
- Analyst Count
- PRFX 1
- GRI 1
- Target Price
- PRFX $12.00
- GRI $12.00
- AVG Volume (30 Days)
- PRFX 238.9K
- GRI 2.6M
- Earning Date
- PRFX 11-13-2024
- GRI 11-13-2024
- Dividend Yield
- PRFX N/A
- GRI N/A
- EPS Growth
- PRFX N/A
- GRI N/A
- EPS
- PRFX N/A
- GRI N/A
- Revenue
- PRFX N/A
- GRI N/A
- Revenue This Year
- PRFX N/A
- GRI N/A
- Revenue Next Year
- PRFX N/A
- GRI N/A
- P/E Ratio
- PRFX N/A
- GRI N/A
- Revenue Growth
- PRFX N/A
- GRI N/A
- 52 Week Low
- PRFX $0.53
- GRI $0.30
- 52 Week High
- PRFX $20.16
- GRI $134.68
- Technical
- Relative Strength Index (RSI)
- PRFX 37.34
- GRI 49.35
- Support Level
- PRFX $0.53
- GRI $0.36
- Resistance Level
- PRFX $0.79
- GRI $0.55
- Average True Range (ATR)
- PRFX 0.06
- GRI 0.06
- MACD
- PRFX 0.04
- GRI 0.02
- Stochastic Oscillator
- PRFX 35.06
- GRI 56.28
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.